Dexketoprofen

證據等級: L5

預測適應症: 10 個

Dexketoprofen: From Acute Pain to Migraine Disorder

One-Sentence Summary

Dexketoprofen is a potent NSAID (the S-enantiomer of ketoprofen) used globally for acute pain management, though it currently holds no market authorization in India. This multi-indication TxGNN analysis identifies migraine disorder as the best-evidenced new indication, supported by 8 clinical trials and 20 publications — reaching L1 evidence level. The highest TxGNN model score belongs to tendinitis (99.90%), where COX inhibition is mechanistically well-justified, though direct clinical evidence for dexketoprofen in that specific indication remains limited.

Quick Overview

Item	Content
Original Indication	No India registration; globally used for acute pain (musculoskeletal, dental, dysmenorrhea)
Top TxGNN Predicted Indication	Tendinitis (TxGNN score: 99.90%, Rank #2446)
Best-Evidenced Predicted Indication	Migraine Disorder (8 clinical trials, 20 publications, L1)
TxGNN Prediction Score (Tendinitis)	99.90%
Evidence Level	Migraine Disorder: L1 / Tendinitis: L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Migraine Disorder: Proceed with Guardrails / Tendinitis: Research Question

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological information, Dexketoprofen is the S-enantiomer of ketoprofen, belonging to the propionic acid class of NSAIDs. It works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, blocking the conversion of arachidonic acid to prostaglandins (PGs) and thromboxanes — the key lipid mediators of pain and inflammation.

For tendinitis (top TxGNN rank), the mechanistic connection is highly plausible: tendinopathic tissue shows elevated PGE2, and COX inhibition directly reduces local prostaglandin concentrations, alleviating inflammatory pain and swelling. NSAIDs are already recognized as first-line agents for tendinitis. The gap here is not mechanistic plausibility, but specific clinical trial evidence for dexketoprofen in this exact indication — the available RCT covers non-traumatic musculoskeletal pain broadly, with tendinitis as one sub-cause.

For migraine disorder (best-evidenced prediction), the mechanistic rationale is well-established: prostaglandins — especially PGE2 — participate in the neuroinflammation and intracranial vasodilation that drive migraine attacks. COX inhibition → decreased PG synthesis → reduced sensitization of the trigeminovascular system → headache relief. This pathway is not theoretical: multiple completed RCTs conducted specifically in emergency departments have directly confirmed intravenous dexketoprofen’s efficacy in aborting acute migraine attacks.

Clinical Trial Evidence

Migraine Disorder (Best-Evidenced Indication)

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02159547	Phase 4	Completed	224	Double-blind placebo-controlled RCT: IV dexketoprofen vs. placebo for migraine attack in ED — primary superiority evidence
NCT01730326	Phase 4	Completed	200	Head-to-head RCT: IV dexketoprofen vs. IV paracetamol for acute migraine attack in emergency service
NCT04533568	Phase 4	Completed	160	RCT: IV dexketoprofen vs. IV ibuprofen for migraine-related headache in ED
NCT04252521	N/A	Completed	150	Double-blind RCT: IV metoclopramide vs. dexketoprofen vs. combination therapy for acute migraine in ED
NCT04372264	Phase 4	Unknown	210	Three-arm RCT: IV dexketoprofen vs. ibuprofen vs. paracetamol — VAS reduction in acute migraine in ED
NCT04519346	N/A	Completed	150	RCT: intradermal mesotherapy vs. systemic therapy (including dexketoprofen) for migraine without aura
NCT05780671	N/A	Completed	160	RCT: supplemental oxygen vs. standard migraine therapy (50 mg dexketoprofen IV + metoclopramide) in ED
NCT06061588	N/A	Completed	140	VR technology for migraine headaches; dexketoprofen serves as standard background treatment in control arm

Tendinitis (Top TxGNN Score Indication)

Currently no registered clinical trials for Dexketoprofen specifically in tendinitis.

Literature Evidence

Migraine Disorder (Best-Evidenced Indication — Top 10 Publications)

PMID	Year	Type	Journal	Key Findings
41321235	2026	Clinical Practice Guideline	Headache	2025 AHS guideline update on parenteral pharmacotherapies for acute migraine in the ED — establishes clinical standards including NSAIDs
31725614	2019	Meta-analysis of RCTs	Medicine	Meta-analysis: dexketoprofen significantly better than placebo for pain control in migraine attacks
37291500	2023	Systematic Review / Meta-analysis	BMC Neurology	Network meta-analysis comparing metoclopramide and other anti-migraine drugs including dexketoprofen
25944813	2016	RCT	Cephalalgia	Randomized placebo-controlled trial: IV dexketoprofen for aborting migraine attack in ED
32359776	2020	RCT	Am J Emerg Med	Double-blind RCT: IV metoclopramide vs. dexketoprofen trometamol vs. combination for acute migraine in ED
24394884	2014	RCT	Emerg Med J	RCT: IV paracetamol vs. dexketoprofen for acute migraine attack in ED — dexketoprofen compared favorably
25056381	2014	RCT	Expert Rev Neurother	Efficacy and tolerability of frovatriptan and dexketoprofen as monotherapies for acute migraine
24412801	2014	Phase II RCT	J Pain	Phase II crossover dose-optimization RCT: dexketoprofen trometamol 25 mg vs. 50 mg vs. placebo — primary endpoint pain-free at 2 h
34085549	2021	RCT	Ann Saudi Med	RCT: intradermal mesotherapy vs. IV dexketoprofen for migraine headache without aura in ED
24363238	2014	RCT	Cephalalgia	RCT: frovatriptan + dexketoprofen (25 or 37.5 mg) vs. frovatriptan alone for migraine with or without aura

Tendinitis (Available Literature)

PMID	Year	Type	Journal	Key Findings
30744914	2019	RCT	Am J Emerg Med	IV dexketoprofen vs. paracetamol in non-traumatic musculoskeletal pain in ED — covers tendinitis, muscle spasm, and joint injuries as a combined endpoint

India Market Information

Dexketoprofen currently has no registered products in India. No authorization records are available.

For reference, dexketoprofen trometamol is marketed in Europe (e.g., as Keral®, Enantyum®) and several other markets for acute pain management. A full CDSCO registration process would be required before any clinical deployment in India.

Summary of All Predicted Indications

Rank	Indication	TxGNN Score	Evidence Level	Recommendation
1	Tendinitis	99.90%	L4	Research Question
2	Fibromyalgia	99.88%	L5	Hold
3	Idiopathic Granulomatous Myositis	99.88%	L5	Hold
4	Myositis Fibrosa	99.88%	L5	Hold
5	Rheumatoid Arthritis	99.88%	L5	Hold
6	Migraine Disorder	99.87%	L1	Proceed with Guardrails
7	Headache Disorder	99.86%	L1	Proceed with Guardrails
8	Migraine with Brainstem Aura	99.86%	L3	Research Question
9	Exostosis	99.85%	L5	Hold
10	Congenital Hypotrichosis Milia	99.83%	L5	Hold

Notes on Hold indications:

Fibromyalgia: Central sensitization dominates; prostaglandins play a limited role; NSAIDs not recommended in current guidelines.
Idiopathic granulomatous myositis / Myositis fibrosa: Rare inflammatory myopathies driven by T-cell granulomatous or fibrotic mechanisms; COX inhibition has no meaningful therapeutic impact.
Rheumatoid arthritis: COX inhibition can reduce symptomatic pain and swelling (PGE2 is elevated in synovial fluid), but RA is an autoimmune disease requiring DMARDs/bDMARDs as backbone therapy; no direct dexketoprofen-specific clinical evidence.
Exostosis / Congenital hypotrichosis milia: Knowledge graph artifacts — structural bone overgrowth and genetic skin disorders with no plausible COX-dependent mechanism.

Safety Considerations

Please refer to the package insert for safety information. Full warnings and contraindications data are not available in this evidence pack.

As a general NSAID class note, the following should be reviewed before clinical use:

Gastrointestinal risk: Risk of GI bleeding and ulceration, especially with prolonged use or in high-risk populations
Renal impairment: NSAIDs can reduce renal prostaglandin synthesis; use with caution in patients with pre-existing renal dysfunction
Cardiovascular risk: Standard NSAID cardiovascular precautions apply
Hypersensitivity: Cross-reactivity risk in patients with aspirin/NSAID hypersensitivity or asthma

Drug-drug interaction data was not found in this evidence pack query.

Conclusion and Next Steps

Decision: Proceed with Guardrails (Migraine Disorder / Headache Disorder)

Rationale: Multiple completed Phase 4 RCTs — including a placebo-controlled trial (n=224) and a meta-analysis of RCTs — confirm IV dexketoprofen’s efficacy in aborting acute migraine attacks in the emergency department. The COX inhibition → prostaglandin reduction → trigeminovascular desensitization mechanism is well-supported by both basic science and clinical data. Both migraine disorder and the broader headache disorder indication reach L1 evidence level.

To proceed, the following is needed:

Regulatory pathway: Initiate CDSCO registration for dexketoprofen trometamol in India (currently no market authorization — a prerequisite for clinical use)
Safety documentation: Retrieve full warnings and contraindications from the package insert (Blocking data gap DG001)
MOA verification: Obtain detailed mechanism of action data from DrugBank (High severity data gap DG002)
DDI profile: Clarify drug-drug interaction profile, especially for co-medications common in migraine management (antiemetics, triptans)
Formulation strategy: IV route has the most evidence (emergency setting); evaluate oral formulation data for outpatient/self-management scenarios
Tendinitis pathway: As the top TxGNN prediction, consider a focused literature review on dexketoprofen in musculoskeletal pain subtypes and assess feasibility of a clinical study specifically in tendinitis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.